Enzymaster
an enzyme-panel screening and directed-evolution house — its Bioengine platform engineers a customer's target reaction into an industrially robust catalyst, and the Ningbo–Germany pair is held up in 2026 Ningbo coverage as a template for China–Germany biotech cooperation.
- Country
- China
Commercial
Coverage
| CN | EU | IN | US | |
|---|---|---|---|---|
| enzymes-biocatalysis | ✓ | ✓ | ✓ | ✓ |
Regulatorsepareachmoa-china
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biocatalysis in petrochemistry | enzymes-biocatalysis | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.